-- Advanced MS therapeutics combined with the innovative
NeuroQuant® software provides invaluable information to
neurologists and radiologists
SAN DIEGO, April 21, 2015 /PRNewswire/ -- CorTechs
Labs, the leading medical software innovator providing solutions
for quantitative brain volume analysis is pleased to announce a
partnership agreement with Novartis Pharma AG, a global
pharmaceutical company. The companies will collaborate to
develop NeuroQuant's powerful brain volume quantification report
targeting the identification, measurement and tracking of brain
volume loss in multiple sclerosis patients.
The resulting report enables clinicians to automatically conduct
accurate and consistent measurements of the whole brain, left and
right thalami and the lateral ventricles out of 3D T1 MRI images.
The report is targeting the identification and tracking of
neurodegeneration in these sub-cortical structures. This
breakthrough solution, which is available both online and as an
installed software solution, provides neurologists and radiologists
with objective support of brain volume loss and its changes over
time and as compared to normative values.
"We're pleased to partner with Novartis to advance the clinical
care and assessment of multiple sclerosis worldwide," said
Guri Stark, CorTechs Labs'
CEO. "We believe this partnership will empower clinicians
with objective quantitative data, while continuing NeuroQuant's
growth momentum. This, in-turn furthers our vision to establish
NeuroQuant as the standard measurement solution for all brain
disorders, including Alzheimer's disease, epilepsy, multiple
sclerosis and traumatic brain injury."
About CorTechs Labs
CorTechs Labs develops and markets cutting-edge brain imaging
solutions used by neurologists and radiologists in hundreds of
clinics and research centers around the world. CorTechs'
flagship product, NeuroQuant®, is a breakthrough, 510(k) cleared
software medical device that makes quantitative analysis of MRI
images of the human brain a routine part of clinical
practice. As the first FDA cleared and CE marked medical
device capable of automatically detecting and quantifying atrophy
in the human brain, NeuroQuant® brings sophisticated,
accurate, and fully automated MRI post-processing capabilities to
the physician's desktop or mobile device. This provides
neurologists, radiologists, and clinical researchers with a
convenient and cost-effective means to quantify atrophy of brain
structures to help diagnose a variety of brain disorders, including
conditions such as Alzheimer's disease, epilepsy, multiple
sclerosis and traumatic brain injury. Please visit
www.cortechslabs.com or www.wholebrainatrophy.com for further
information.